Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Omacetaxine Mepesuccinate

FDA-approved product (powder, subcutaneous), marketed as Synribo.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Omacetaxine Mepesuccinate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Other antineoplastic agents
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA59.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli37.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Omacetaxine Mepesuccinate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Omacetaxine Mepesuccinate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Selinexor Combined With Induction Chemotherapy for Children With NUP98-positive AML

    NCT07437170 · start 2024-01-01

    Registered record
    Registry ID
    NCT07437170
    Conditions
    Acute Myeloid Leukemia; Pediatric Acute Myeloid Leukemia; NUP98 Fusion-positive Acute Myeloid Leukemia
    Interventions
    Selinexor; ZJCH-AML Standardized Chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2024-01-01
    Completion
    2027-12-31
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia; Pediatric Acute Myeloid Leukemia; NUP98 Fusion-positive Acute Myeloid Leukemia
    InterventionSelinexor; ZJCH-AML Standardized Chemotherapy
    PhasePhase 2
    Registry statusActive not recruiting

  • Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients

    NCT05805072 · start 2023-05-01

    Registered record
    Registry ID
    NCT05805072
    Conditions
    Relapsed/Refractory AML
    Interventions
    Selinexor; Homoharringtonine; Cytarabine; Aclacinomycin; Granulocyte Colony-Stimulating Factor; Decitabine; Azacitidine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2023-05-01
    Completion
    2024-06-30
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed/Refractory AML
    InterventionSelinexor; Homoharringtonine; Cytarabine; Aclacinomycin +3 more
    PhaseNot applicable
    Registry statusUnknown

  • Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia

    NCT05726110 · start 2023-01-29

    Registered record
    Registry ID
    NCT05726110
    Conditions
    Relapsed or Refractory Acute Myeloid Leukemia
    Interventions
    Selinexor; Homoharringtonine; Daunorubicin; Cytarabine; Granulocyte Colony-Stimulating Factor; Aclacinomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2023-01-29
    Completion
    2024-12-31
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed or Refractory Acute Myeloid Leukemia
    InterventionSelinexor; Homoharringtonine; Daunorubicin; Cytarabine +2 more
    PhasePhase 3
    Registry statusRecruiting

  • Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for de Novo Acute Myeloid Leukemia

    NCT05906914 · start 2022-10-26

    Registered record
    Registry ID
    NCT05906914
    Conditions
    Acute Myeloid Leukemia, Adult
    Interventions
    cladribine + homoharringtonine + cytarabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2022-10-26
    Completion
    2025-10-31
    Enrolment
    65

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia, Adult
    Interventioncladribine + homoharringtonine + cytarabine
    PhasePhase 2
    Registry statusCompleted

  • Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia (AML)

    NCT04926285 · start 2022-06-21

    Registered record
    Registry ID
    NCT04926285
    Conditions
    Relapsed or Refractory Hematologic Malignancies
    Interventions
    Omacetaxine; Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-06-21
    Completion
    2025-02-06
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed or Refractory Hematologic Malignancies
    InterventionOmacetaxine; Venetoclax
    PhasePhase 1
    Registry statusCompleted

  • VAH Versus VA for Salvage Therapy of R/R-AML

    NCT05457361 · start 2022-03-01

    Registered record
    Registry ID
    NCT05457361
    Conditions
    Venetoclax Combined With Azacitidine Plus Homoharringtonine; Venetoclax Combined With Azacitidine
    Interventions
    VEN combined with azacitidine plus homoharringtonine; VEN combined with azacitidine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2022-03-01
    Completion
    2023-12-31
    Enrolment
    162

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVenetoclax Combined With Azacitidine Plus Homoharringtonine; Venetoclax Combined With Azacitidine
    InterventionVEN combined with azacitidine plus homoharringtonine; VEN combined with azacitidine
    PhasePhase 3
    Registry statusUnknown

  • Clinical Study Protocol of Venetoclax Combined With Azacitidine and Harringtonine in the Treatment of sAML

    NCT05513131 · start 2021-09-30

    Registered record
    Registry ID
    NCT05513131
    Conditions
    Secondary Acute Myeloid Leukemia
    Interventions
    Venetoclax；Azacitidine；Homoharringtonine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2021-09-30
    Completion
    2025-09-30
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSecondary Acute Myeloid Leukemia
    InterventionVenetoclax；Azacitidine；Homoharringtonine
    PhasePhase 2
    Registry statusUnknown

  • New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

    NCT05029141 · start 2021-09-01

    Registered record
    Registry ID
    NCT05029141
    Conditions
    Acute Myeloid Leukemia; Refractory Acute Leukemia; Relapsed Adult AML
    Interventions
    CAHAG regimen; Placebo regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2021-09-01
    Completion
    2027-08-31
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia; Refractory Acute Leukemia; Relapsed Adult AML
    InterventionCAHAG regimen; Placebo regimen
    PhasePhase 2
    Registry statusActive not recruiting

  • Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML

    NCT04501120 · start 2020-09-28

    Registered record
    Registry ID
    NCT04501120
    Conditions
    Relapsed/Refractory Acute Myeloid Leukaemia; Myeloid Malignancy
    Interventions
    Lisaftoclax (APG-2575); Reduced-dose HHT; standard-dose HHT; Azacitidine; Lisaftoclax (APG-2575); olverembatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2020-09-28
    Completion
    2029-09
    Enrolment
    682

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed/Refractory Acute Myeloid Leukaemia; Myeloid Malignancy
    InterventionLisaftoclax (APG-2575); Reduced-dose HHT; standard-dose HHT; Azacitidine +2 more
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Efficacy of HAD Induction With Intensified Cytarabine in Newly-diagnosed CEBPA Double Mutated Acute Myeloid Leukemia

    NCT04415008 · start 2020-06-01

    Registered record
    Registry ID
    NCT04415008
    Conditions
    CEBPA Double Mutation; Acute Myeloid Leukemia
    Interventions
    HAD induction with intermediate dose cytarabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2020-06-01
    Completion
    2027-06-01
    Enrolment
    61

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCEBPA Double Mutation; Acute Myeloid Leukemia
    InterventionHAD induction with intermediate dose cytarabine
    PhasePhase 2
    Registry statusActive not recruiting

  • Azacitidine and Homoharringtonine in JMML

    NCT04505995 · start 2020-01-01

    Registered record
    Registry ID
    NCT04505995
    Conditions
    JMML
    Interventions
    Azacitidine and homoharringtonine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2020-01-01
    Completion
    2025-01-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionJMML
    InterventionAzacitidine and homoharringtonine
    PhaseNot applicable
    Registry statusUnknown

  • Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML

    NCT04248595 · start 2019-12-01

    Registered record
    Registry ID
    NCT04248595
    Conditions
    Acute Myeloid Leukemia
    Interventions
    Homoharringtonine; Azacitidine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2019-12-01
    Completion
    2022-12-30
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia
    InterventionHomoharringtonine; Azacitidine
    PhasePhase 2
    Registry statusUnknown

  • A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase

    NCT04126681 · start 2019-10-21

    Registered record
    Registry ID
    NCT04126681
    Conditions
    Chronic Myeloid Leukemia, Chronic Phase
    Interventions
    HQP1351; Hydroxyurea or Interferon-based therapy; Homoharringtonine; Imatinib, Dasatinib or Nilotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-10-21
    Completion
    2024-08-01
    Enrolment
    144

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Myeloid Leukemia, Chronic Phase
    InterventionHQP1351; Hydroxyurea or Interferon-based therapy; Homoharringtonine; Imatinib, Dasatinib or Nilotinib
    PhasePhase 2
    Registry statusCompleted

  • A Study of Azacitidine for Patients With Int/High -Risk MDS and AML-MRC

    NCT03978364 · start 2019-06-01

    Registered record
    Registry ID
    NCT03978364
    Conditions
    Myelodysplastic Syndromes,Acute Myeloid Leukemia
    Interventions
    Azacitidine combined HHT; Azacitidine regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2019-06-01
    Completion
    2022-12-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyelodysplastic Syndromes,Acute Myeloid Leukemia
    InterventionAzacitidine combined HHT; Azacitidine regimen
    PhasePhase 3
    Registry statusUnknown

  • Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients

    NCT04446130 · start 2019-01-01

    Registered record
    Registry ID
    NCT04446130
    Conditions
    Induction Chemotherapy; Acute T-Lymphocytic Leukemia; T-cell Lymphoblastic Lymphoma Leukemia; T-cell/Myeloid Mixed Phenotype Acute Leukemia
    Interventions
    Decitabine combined with HAAG Regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2019-01-01
    Completion
    2024-01-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInduction Chemotherapy; Acute T-Lymphocytic Leukemia; T-cell Lymphoblastic Lymphoma Leukemia; T-cell/Myeloid Mixed Phenotype Acute Leukemia
    InterventionDecitabine combined with HAAG Regimen
    PhasePhase 3
    Registry statusUnknown